[Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids / Q000037:antagonists & inhibitors; D002490:Central Nervous System / Q000187:drug effects; D002493:Central Nervous System Diseases / Q000139:chemically induced; D017277:Drug Approval; D005858:Germany; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced; D024821:Metabolic Syndrome / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000077285:Rimonabant; D014481:United States; D014486:United States Food and Drug Administration; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant